Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
Anatole Besarab, Robert Provenzano, Joachim Hertel, Raja Zabaneh, Stephen J Klaus, Tyson Lee, Robert Leong, Stefan Hemmerich, Kin-Hung Peony Yu, Thomas B Neff, Anatole Besarab, Robert Provenzano, Joachim Hertel, Raja Zabaneh, Stephen J Klaus, Tyson Lee, Robert Leong, Stefan Hemmerich, Kin-Hung Peony Yu, Thomas B Neff
Abstract
Background: Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb response) and safety of roxadustat in anemic nondialysis-dependent chronic kidney disease (NDD-CKD) subjects.
Methods: NDD-CKD subjects with hemoglobin (Hb) ≤11.0 g/dL were sequentially enrolled into four dose cohorts and randomized to roxadustat or placebo two times weekly (BIW) or three times weekly (TIW) for 4 weeks, in an approximate roxadustat:placebo ratio of 3:1. Efficacy was assessed by (i) mean Hb change (ΔHb) from baseline (BL) and (ii) proportion of Hb responders (ΔHb ≥ 1.0 g/dL). Pharmacodynamic evaluation was performed in a subset of subjects. Safety was evaluated by adverse event frequency/severity.
Results: Of 116 subjects receiving treatment, 104 completed 4 weeks of dosing and 96 were evaluable for efficacy. BL characteristics for roxadustat and placebo groups were comparable. In roxadustat-treated subjects, Hb levels increased from BL in a dose-related manner in the 0.7, 1.0, 1.5 and 2.0 mg/kg groups. Maximum ΔHb within the first 6 weeks was significantly higher in the 1.5 and 2.0 mg/kg groups than in the placebo subjects. Hb responder rates were dose dependent and ranged from 30% in the 0.7 mg/kg BIW group to 100% in the 2.0 mg/kg BIW and TIW groups versus 13% in placebo.
Conclusions: Roxadustat transiently and moderately increased endogenous erythropoietin and reduced hepcidin. Adverse events were similar in the roxadustat and placebo groups. Roxadustat produced dose-dependent increases in blood Hb among anemic NDD-CKD patients in a placebo-controlled trial.
Clinical trials registration: Clintrials.gov #NCT00761657.
Keywords: HIF-PHI; anemia; chronic kidney disease; erythropoietin; hepcidin.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA.
Figures
References
- Collins AJ, Ma JZ, Xia A et al. . Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998; 32: S133–S141
- Coresh J, Selvin E, Stevens LA et al. . Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038–2047
- Eschbach JW, Egrie JC, Downing MR et al. . Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73–78
- Regidor DL, Kopple JD, Kovesdy CP et al. . Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181–1191
- Revicki DA, Brown RE, Feeny DH et al. . Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548–554
- Benz R, Schmidt R, Kelly K et al. . Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 215–221
- U.S. Renal Data System. 2013 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; (1 October 2014, date last accessed)
- Minutolo R, Locatelli F, Gallieni M et al. . Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant 2013; 28: 3035–3045
- Yan G, Cheung AK, Ma JZ et al. . The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD. Clin J Am Soc Nephrol 2013; 8: 610–618
- Valderrabano F, Horl WH, Macdougall IC et al. . PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2003; 18: 89–100
- Perez-Garcia R, Martin-Malo A, Fort J et al. . Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER—a multicentre, prospective, observational cohort study. Nephrol Dial Transplant 2009; 24: 578–588
- Pfeffer MA, Burdmann EA, Chen CY et al. . A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019–2032
- Singh AK, Szczech L, Tang KL et al. . Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–2098
- Epogen® Package Insert, 2009. (20 March 2015, date last accessed)
- Gill KS, Muntner P, Lafayette RA et al. . Red blood cell transfusion use in patients with chronic kidney disease. Nephrol Dial Transplant 2013; 28: 1504–1515
- Seliger S, Fox KM, Gandra SR et al. . Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study. Clin J Am Soc Nephrol 2010; 5: 882–888
- Levin A. The treatment of anemia in chronic kidney disease: understandings in 2006. Curr Opin Nephrol Hypertens 2007; 16: 267–271
- Mohanram A, Zhang Z, Shahinfar S et al. . Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004; 66: 1131–1138
- Karpinski M, Pochinco D, Dembinski I et al. . Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 2004; 15: 818–824
- Obrador GT, Macdougall IC. Effect of red cell transfusions on future kidney transplantation. Clin J Am Soc Nephrol 2013; 8: 852–860
- Macdougall IC. Recent advances in erythropoietic agents in renal anemia. Semin Nephrol 2006; 26: 313–318
- Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol 2010; 299: F1–F13
- Levey AS, Bosch JP, Lewis JB et al. . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–470
- Macdougall IC, Walker R, Provenzano R et al. . C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3: 337–347
- Ross SP, McCrea JB, Besarab A. Erythropoietin response to blood loss in hemodialysis patients is blunted but preserved. ASAIO J 1994; 40: M880–M885
- Kato A, Hishida A, Kumagai H et al. . Erythropoietin production in patients with chronic renal failure. Ren Fail 1994; 16: 645–651
- Milledge JS, Cotes PM. Serum erythropoietin in humans at high altitude and its relation to plasma renin. J Appl Physiol 1985; 59: 360–364
- Cheung WK, Goon BL, Guilfoyle MC et al. . Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1998; 64: 412–423
- Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2: 1274–1282
- Szczech LA, Barnhart HX, Inrig JK et al. . Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791–798
- Zhang Y, Thamer M, Stefanik K et al. . Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866–876
- Erslev AJ. Erythropoietin. N Engl J Med 1991; 324: 1339–1344
- Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14–31
- Spinowitz BS, Kausz AT, Baptista J et al. . Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599–1605
- Locatelli F, Olivares J, Walker R et al. . Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741–747
- Macdougall IC, Wiecek A, Tucker B et al. . Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol 2011; 6: 2579–2586
- Roger SD, Locatelli F, Woitas RP et al. . C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant 2011; 26: 3980–3986
- Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006; 26: 323–342
- Peyssonnaux C, Zinkernagel AS, Schuepbach RA et al. . Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117: 1926–1932
- Shah YM, Matsubara T, Ito S et al. . Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab 2009; 9: 152–164
- Anderson ER, Xue X, Shah YM. Intestinal hypoxia-inducible factor-2α (HIF-2α) is critical for efficient erythropoiesis. J Biol Chem 2011; 286: 19533–19540
Source: PubMed